Biological Information
Background Information:
Lysyl Oxidase Homolog 2 (LOXL2) is a member of lysyl oxidase-like (LOXL) gene family which includes LOXL1 through LOXL4. LOX catalyzes the crosslinking of extracellular matrix (ECM) such as collagen and elastin. LOXL2 is highly expressed in uterus and prostate. LOXL2 is also upregulated in many cancer cells, remodels tumor microenvironment as regulator of carcinogenesis. LOXL2 may serve as a potential therapeutic target against cancer.
Family:
Oxidoreductase
Sub Family:
Oxidase
Class:
Oxidase
Protein Name:
LOXL2
Uniprot Number:
Q9Y4K0
Protein Aliases:
Lysyl oxidase-like protein 2
Gene Name:
LOXL2
Gene ID:
4017
Gene Aliases:
WS9-14; LOR
Accession Number:
NM_002318
Organism:
Human
Construct Details:
Full length, Recombinant
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
Spectrofluorimetry
Measured Response:
Fluorescence
Testing Information
Procedure Summary:
Human recombinant LOXL2 enzyme expressed in mouse myeloma cells is used. Test compound and/or vehicle is preincubated with 4 µg/ml active enzyme in modified sodium borate buffer pH 8.0 for 15 minutes at 37°C. The reaction is initiated by addition of 300 uM cadaverine substrate and Amplex Ultrared for another 30 minute incubation period. Determination of the amount of resorufin formed is read spectrofluorimetrically at 544 nm/590 nm. Compounds are screened at 10 uM.
Substrate:
300 µM Cadavertine
Incubation:
30 min at 37°C
Control Inhibitor:
PXS-5153A
Criteria For Significance:
≥ 50% of max stimulation or inhibition
Test Concentration / Dose:
Suggested concentration for initial testing is 10 uM
Test Sample Requirements:
Minimum for 1) Screen: 25 μl of 10 mM stock -OR- 1 mg (pre-weighed). 2) Dose Response: 60 μl of 10 mM stock -OR- 1 mg (pre-weighed).
Minimum Order Quantity:
2
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Inflammation/Allergy
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
RELATED SOLUTIONS